“We demonstrate superior case-level sensitivity of a clinically integrated AI-based tool over standard radiology reports
(93.3% for the AI software vs 58.3% for a standard radiology report), relative to a consensus ground truth, with minimal loss of specificity.”
For more information, please click here for our publication “A Real-World Clinical Validation for AI-based MRI Monitoring in Multiple Sclerosis”.
This AI-based iQ (intelligent Quantitation) software future proofs clinical and research radiology reporting with accurate, reproducible measurement of brain tissue and brain pathology across a range of neurological diseases:
Detection of disease progression, even before symptomatic worsening, is key to delivering precision care and preventing neurological disability:
iQ-MS – Next generation lesion activity assessment:
-
Quantitative, precise, lesion assessment [existing (red), new (blue), enlarging (green) lesions]
-
Lesion number, volume and change from prior study.
SNAC’s iQ-MS™ produces real-time, customisable reports to monitor the changes in lesions and brain volume changes, including:
-
Measurement of FLAIR white matter hyperintensities (WMH) and contrast-enhancing T1 hyperintensities.
-
Comparison between present scan and previous timepoint to measure brain volume changes, WMH changes, and changes in thalamus.
-
Volumetric comparison to healthy cohort and patient cohort to display a more precise disease progression stage.